| 2026-03-18 | Press release | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results |
| 2026-03-10 | Document | View HTML |
| 2026-02-18 | Press release | Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-01-26 | Press release | Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Ce |
| 2026-01-05 | Press release | Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients |
| 2025-11-14 | Press release | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 2025-11-05 | Press release | Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors |
| 2025-11-03 | Press release | Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th |
| 2025-10-06 | Press release | Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program |
| 2025-08-28 | Press release | Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference |
| 2025-08-26 | Press release | Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed |
| Press release | Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference |
| Press release | Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-An |
| Press release | Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T C |
| Press release | Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies |
| 2025-04-24 | Document | View HTML |
| Press release | Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference |
| 2025-03-31 | Press release | Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results |
| Press release | Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference |
| Press release | Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma |
| Press release | Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium |
| Press release | Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit |
| 2024-11-14 | Press release | Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 2024-08-14 | Press release | Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates |
| 2024-05-15 | Press release | Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates |
| Press release | Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeuti |
| 2024-03-25 | Press release | Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results |
| Press release | Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference |
| Press release | Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Na |
| Press release | Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization |
| Press release | Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “ |
| Press release | Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T |
| 2023-11-09 | Press release | Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates |
| Press release | Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse |
| Press release | Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference |
| 2023-08-14 | Press release | Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update |
| Press release | Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-S |
| Press release | Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T |
| Press release | European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment o |
| Press release | Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration |